Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea · Delayed Price · Currency is KRW 13,400
-1,200 (-8.22%)
Apr 30, 2026, 3:30 PM KST
Hyundai Bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,517 | 15,050 | 9,481 | 7,852 | 9,241 |
Other Revenue | - | -0 | -0 | - | - |
| 3,517 | 15,050 | 9,481 | 7,852 | 9,241 | |
Revenue Growth (YoY) | -76.63% | 58.73% | 20.76% | -15.04% | -26.14% |
Cost of Revenue | 3,519 | 3,258 | 4,490 | 5,140 | 6,012 |
Gross Profit | -1.69 | 11,792 | 4,992 | 2,712 | 3,229 |
Selling, General & Admin | 9,896 | 7,598 | 7,846 | 6,542 | 6,647 |
Research & Development | 7,595 | 3,055 | 6,401 | 16,456 | 4,763 |
Amortization of Goodwill & Intangibles | - | - | 328.42 | 489.85 | 1,228 |
Other Operating Expenses | 32.24 | 38.4 | 42.25 | 27.37 | 61.28 |
Operating Expenses | 18,159 | 10,959 | 14,795 | 29,023 | 12,519 |
Operating Income | -18,161 | 833.79 | -9,804 | -26,311 | -9,289 |
Interest Expense | -2,435 | -2,313 | -314.57 | -448.65 | -3,003 |
Interest & Investment Income | 1,326 | 210.7 | 669.19 | 536.69 | 291.71 |
Earnings From Equity Investments | -4,766 | -5,730 | - | 8,834 | 93.91 |
Currency Exchange Gain (Loss) | -38.16 | 3.73 | -68.67 | 48.15 | 20.39 |
Other Non Operating Income (Expenses) | 1,978 | 94.13 | -335.47 | -182.82 | -404.46 |
EBT Excluding Unusual Items | -22,095 | -6,901 | -9,853 | -17,524 | -12,291 |
Gain (Loss) on Sale of Investments | -9.04 | 14.05 | 123.67 | 910.99 | - |
Asset Writedown | - | - | -4,769 | - | -7,517 |
Pretax Income | -22,105 | -6,887 | -14,498 | -16,613 | -19,808 |
Income Tax Expense | 3.89 | - | 1.04 | -805.47 | 243.5 |
Earnings From Continuing Operations | -22,108 | -6,887 | -14,499 | -15,807 | -20,051 |
Earnings From Discontinued Operations | -19.95 | -42.82 | - | - | - |
Net Income | -22,128 | -6,930 | -14,499 | -15,807 | -20,051 |
Net Income to Common | -22,128 | -6,930 | -14,499 | -15,807 | -20,051 |
Shares Outstanding (Basic) | 105,373 | 12,832 | 80 | 79 | 74 |
Shares Outstanding (Diluted) | 105,373 | 12,832 | 80 | 79 | 74 |
Shares Change (YoY) | 721.14% | 16030.92% | 1.04% | 6.64% | 2.79% |
EPS (Basic) | -0.21 | -0.54 | -182.26 | -200.77 | -271.58 |
EPS (Diluted) | -0.21 | -0.54 | -182.50 | -201.00 | -271.58 |
Free Cash Flow | -18,244 | 2,087 | -6,548 | -18,087 | -4,285 |
Free Cash Flow Per Share | -0.17 | 0.16 | -82.31 | -229.72 | -58.04 |
Gross Margin | -0.05% | 78.35% | 52.65% | 34.53% | 34.95% |
Operating Margin | -516.32% | 5.54% | -103.40% | -335.10% | -100.52% |
Profit Margin | -629.12% | -46.04% | -152.92% | -201.33% | -216.97% |
Free Cash Flow Margin | -518.69% | 13.87% | -69.06% | -230.36% | -46.37% |
EBITDA | -16,855 | 1,468 | -8,369 | -24,529 | -6,586 |
EBITDA Margin | - | 9.75% | -88.27% | - | -71.27% |
D&A For EBITDA | 1,306 | 633.82 | 1,435 | 1,782 | 2,703 |
EBIT | -18,161 | 833.79 | -9,804 | -26,311 | -9,289 |
EBIT Margin | - | 5.54% | -103.40% | - | -100.52% |
Advertising Expenses | 1,546 | 267.64 | 996.63 | 965.59 | 1,497 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.